Avenna LifeBook (AvLB): A bioinformatics system to support a real world, life-course approach to precision medicine for inflammatory bowel disease (IBD)
Lead Participant:
AVENNA LTD
Abstract
**Vision**
This project is to develop critical components of Avenna LifeBook (AvLB) -- a bioinformatics system to support our precision medicine (PM) programmes for high-burden chronic inflammatory diseases (cIDs).
AvLB is the first module in Avalon, our bioinformatics system to produce real-world evidence (RWE) on cID patients' health and disease trajectories. AvLB's function is to gather, clean, and prepare real-world data (RWD) and other relevant health information on each individual for transformation to RWE by Avalon's PM modelling systems.
**Objectives**
In this project, we will develop core AvLB data structures and algorithms to cleanse, curate, and annotate datasets on patients with inflammatory bowel disease (IBD). The cleansed data would then be ready to be analysed by ProDroma-IBD, a novel AI system we are developing to predict the likely future health trajectories of IBD patients and their responses to anti-inflammatory treatments.
**Focus**
Typically, the RWD to be cleansed and curated by AvLB would be large, complex, incomplete, skewed, and partially corrupted. In this project, we will focus on a wide range of IBD patient datasets including :
* Genomics profiles.
* Relevant omics data -- e.g. profiles from Avenna's GlyHealth-IBD assay and epigenetic, microbiome, metabolomics, and proteomics tests. GlyHealth-IBD is our novel prognostic and predictive glycomics biomarker being co-developed with Ludger.
* IBD-specific clinical data -- including endoscopy images, and blood and stool analyses.
* Patient-supplied data -- including digital information, e.g. symptoms tracking information from Ampersand Health's MyIBDCare app, food, movement, and sleep data.
Most of the datasets would be time-series profiles relevant to IBD disease progression and gut healing in response to effective anti-inflammatory therapy.
The patient data for this project will be provided by some of our clinical and Medtech development partners. Those include the NIHR IBD BioResource, Barts Hospital, and Ampersand Health.
**Innovation**
AvLBD must curate patient data to ease complex AI analyses by ProDroma-IBD. To achieve that, we use methods we built on Emoiré, our novel systems science framework to support the systematic translation of PM technologies for cIDs.
Emoiré deals with patterns in human life, particularly those for health determinants that shape an individual's life trajectory. Its main tenet is that complex patterns in our lives arise from interactions of simple components. Emoiré uses mathematical models and tools to help us deal with the chaos and complexity of RWD and RWE. We must analyse these effectively to advance precision medicine for chronic inflammatory diseases, including PM for IBD.
This project is to develop critical components of Avenna LifeBook (AvLB) -- a bioinformatics system to support our precision medicine (PM) programmes for high-burden chronic inflammatory diseases (cIDs).
AvLB is the first module in Avalon, our bioinformatics system to produce real-world evidence (RWE) on cID patients' health and disease trajectories. AvLB's function is to gather, clean, and prepare real-world data (RWD) and other relevant health information on each individual for transformation to RWE by Avalon's PM modelling systems.
**Objectives**
In this project, we will develop core AvLB data structures and algorithms to cleanse, curate, and annotate datasets on patients with inflammatory bowel disease (IBD). The cleansed data would then be ready to be analysed by ProDroma-IBD, a novel AI system we are developing to predict the likely future health trajectories of IBD patients and their responses to anti-inflammatory treatments.
**Focus**
Typically, the RWD to be cleansed and curated by AvLB would be large, complex, incomplete, skewed, and partially corrupted. In this project, we will focus on a wide range of IBD patient datasets including :
* Genomics profiles.
* Relevant omics data -- e.g. profiles from Avenna's GlyHealth-IBD assay and epigenetic, microbiome, metabolomics, and proteomics tests. GlyHealth-IBD is our novel prognostic and predictive glycomics biomarker being co-developed with Ludger.
* IBD-specific clinical data -- including endoscopy images, and blood and stool analyses.
* Patient-supplied data -- including digital information, e.g. symptoms tracking information from Ampersand Health's MyIBDCare app, food, movement, and sleep data.
Most of the datasets would be time-series profiles relevant to IBD disease progression and gut healing in response to effective anti-inflammatory therapy.
The patient data for this project will be provided by some of our clinical and Medtech development partners. Those include the NIHR IBD BioResource, Barts Hospital, and Ampersand Health.
**Innovation**
AvLBD must curate patient data to ease complex AI analyses by ProDroma-IBD. To achieve that, we use methods we built on Emoiré, our novel systems science framework to support the systematic translation of PM technologies for cIDs.
Emoiré deals with patterns in human life, particularly those for health determinants that shape an individual's life trajectory. Its main tenet is that complex patterns in our lives arise from interactions of simple components. Emoiré uses mathematical models and tools to help us deal with the chaos and complexity of RWD and RWE. We must analyse these effectively to advance precision medicine for chronic inflammatory diseases, including PM for IBD.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| AVENNA LTD | £48,740 | £ 48,740 |
Participant |
||
| MENDEZ WEISS & CO LTD |
People |
ORCID iD |
| Paul Plume (Project Manager) |